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ABSTRACT. Background: Neonates are at high risk for the de-
velopment of parenteral nutrition-associated cholestasis when
receiving a prolonged course of total parenteral nutrition (TPN).
Although this cholestasis is of unknown etiology, it may result
from a lack of gastrointestinal hormone formation, including
cholecystokinin, which normally occurs after enteral feedings.
Methods: Two groups of neonates were studied. The treatment
group consisted of 21 consecutive, prospectively enlisted neo-
nates receiving TPN for > 14 days. The nontreatment group con-
sisted of 21 infants from the 2 years preceding the study who
were matched to the treatment group by gestational age, diagno-
sis, and duration of TPN. The major outcome determinant was
direct bilirubin. Cholestasis was defined as a direct bilirubin >2.0
mg/dL and was considered severe if the direct bilirubin was >5.0
mg/dL after other causes were ruled out. Results: The mean di-
rect bilirubin levels in the nontreated group progressively rose
over time, whereas the mean direct bilirubin in the treated group
remained level. The incidence of infants with a direct bilirubin
>2.0 mg/dL was 24% and 43% in the CCK+ and CCK- groups,
respectively, and was not significant (p = .14). The percentage of
infants with a direct bilirubin >5.0 mg/dL was 9.5% and 38% in
the treatment and nontreatment groups, respectively, and was
significant, p= .015. Conclusions: Levels of direct bilirubin were
lower in the treated compared with the nontreated group. These
findings suggest that cholecystokinin prophylaxis in high-risk
neonates may help prevent the development of parenteral nutri-
tion-associated cholestasis. (journal of Parenteral and Enteral
Nutrition 21:100-103, 1997)
Parenteral nutrition-associated cholestasis (PNAC) is
a common problem encountered in neonates who cannot
receive adequate amounts of enteral nutrition for pro-
longed periods of time. 1-3 The etiology of this disorder re-
mains unclear. One possible explanation, however, is that
a lack of enteral feeding leads to diminished bile flow.
Because cholecystokinin (CCK) has been demonstrated
to increase both intrahepatic and extrahepatic bile flow, 4-6
we hypothesized that CCK may prevent the development
of PNAC. Our group and others have recently reported
that CCK can decrease the level of hyperbilirubinemia in
neonates who have already developed PNAC.7,8 The aim
of this study was to determine if prophylactically admin-
istered CCK would reduce the severity of PNAC in neo-
nates at risk for the development of this process.
MATERIALS AND METHODS
Two groups of infants receiving total parenteral nutri-
tion (TPN) were studied. The treatment group (CCK+)
consisted of 26 neonates who were consecutively enrolled
and followed in a prospective fashion. All patients had a
disease process (eg, prematurity [< 1500 g], gastroschisis,
necrotizing enterocolitis, or congenital diaphragmatic her-
nia) in which it was thought that the patient would require
at least 2 weeks of TPN. A synthetic form of cholecystoki-
nin-octapeptide (Sincalide; Bracco Diagnostics, Princeton,
NJ, referred to as CCK for the remainder of this paper)
was given at a dose of 0.02 pg/kg/dose IV, twice a day for
14 days. Dosing was increased to 0.04 pg/kg/dose IV three
times a day if TPN was continued for > 14 days. CCK ad-
ministration was terminated when 50% or more of the in-
fants nutritional intake was received by the enteral route
or upon discharge from the neonatal intensive care unit.
Infants were excluded from the study if they had liver dys-
function or hyperbilirubinemia from other causes (eg, con-
genital obstruction of the biliary tree, hemolysis, or if they
were receiving a course of extracorporeal membrane oxy-
genation, in which hemolysis may occur). Infants were also
excluded if they had (or were suspected of having) a meta-
bolic defect or if they had been receiving TPN for > 10
days prior to starting on the study. Infants were removed
from the study if they achieved >50% of their caloric in-
take by the enteral route before completing at least 14 days
of the study.
The nontreatment group (CCK-), consisted of 21 neo-
nates who were matched to the study patients by gesta-
tional age (within 1 week), principal clinical diagnosis and
duration of TPN (within 1 week). All control neonates had
been treated in the same neonatal intensive care unit over
the previous 2 years. All patients received the same type
of parenteral nutrition. The crystalline amino acid was
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Aminosyn (Abbott Laboratories, Abbott Park, IL) and the
lipid was Liposyn 20% (Abbott Laboratories).
The primary outcome measure was direct bilirubin.
PNAC was defined, based on previously established defi-
nitions, as a direct bilirubin >2.0 mg/dL after a prolonged
course of TPN (ie, >2 weeks) and when other causes were
ruled out.’ Severe PNAC was defined as a direct bilirubin
>5.0 mg/dL. Severe PNAC was defmed by previous reports,
which have demonstrated a high degree of mortality asso-
ciated with a direct bilirubin in this range. 10 Direct biliru-
bin levels were obtained on a weekly basis while all
infants were on the study for both study groups. Thus,
bilirubin levels were obtained at similar time periods and
intervals in each group, which allowed for a ready com-
parison. Other etiologies of hyperbilirubinemia were evalu-
ated by clinical inspection, ultrasonography of the
hepatobiliary tree, as well as hepatitis and TORCH titers.
An open liver biopsy was done in three patients after the
termination of the study in conjunction with another op-
erative procedure (closure of ostomies). A cholestatic his-
tologic appearance was present in all cases, consistent with
PNAC.
A data acquisition sheet was maintained on each patient.
Direct, indirect, and total bilirubins, alkaline phosphatase,
alanine transaminase (ALT), asparatate transaminase
(AST), and lactate dehydrogenase (LDH) were measured
on a weekly basis, starting at the initiation of the study
and ending at the completion of the study. Monitoring also
included the amount and type of parenteral and enteral
nutrition. Mean total calories and amounts of protein and
lipid were calculated weekly and expressed as the mean
amount delivered each day. Additionally, clinical diagno-
sis, birth weight, gestational age, daily body weights, op-
erative procedures, complications, and drugs administered
were recorded. Adverse reactions to CCK were monitored
on a daily basis.
This study was approved by the University of Michigan’s
Investigational Review Board as well as by the Food and
Drug Administration, which considered Sincalide an in-
vestigational drug in the neonatal period. Informed con-
sent was obtained from the infant’s parent(s) or
guardian(s) prior to beginning the study.
Results are expressed as means ± SD. The McNemar’s
test, linear regression analysis, and Fisher’s Exact Test
were used for statistical analysis; ap value <.05 was con-
sidered significant.
RESULTS
Twenty-six neonates were recruited into the treatment
group (CCK+). Five infants were removed from the study
because they achieved >50% of nutritional intake by the
enteral route before receiving 14 days of CCK. Twenty-
one neonates completed the study. CCK treatment was
discontinued for one patient in the treatment group at 21 1
days of treatment because of a persistent delay in gastric
emptying that was thought to be due to the drug. Follow-
ing cessation of the drug, no improvement in feeding tol-
erance or gastric emptying was noted. Patients in the
CCK+ group received a mean of 34::!:: 33 days of CCK treat-
ment (range 14 to 116 days). Table I shows the demo-
graphic characteristics of the two groups.
The diagnoses of the patients in each study group were
as follows: gastroschisis (n = 5); necrotizing enterocolitis
TABLE I
Demographic data in the cholecystokinin-treated vs -nontreated groups
Values are number of subjects with percentages in parentheses.
(n = 10); congenital diaphragmatic hernia (n = 3); and low-
birth-weight infants (n = 3). As can be seen, the majority
of the neonates had an abnormality of the gastrointestinal
tract that prevented them from taking enteral feedings. Of
the 10 infants in each group who were diagnosed with
necrotizing enterocolitis (NEC), 6 were treated conserva-
tively with antibiotics and nasogastric decompression and
4 underwent a surgical exploration with resection of in-
volved intestine.
Three patients died in each group, from either their pri-
mary disease process, sepsis, or liver failure secondary to
the cholestasis. All deaths occurred >2 weeks after the
termination of the study. Two patients in both the CCK+
and the CCK- groups developed a septic episode, defined
as a blood culture positive for a bacteria, during the course
of the study.
Mean total calories (enteral and parenteral combined)
and protein and fat delivery (from parenteral nutrition)
were not statistically different (p > .05) between the two
groups except for a higher protein delivery in the CCK+
group during the second week of the study.
Bilirubin levels are shown in Figure 1. Because of a lim-
ited number of patients remaining on the study after 7
weeks, only the first 7 weeks of the study are shown in
Figure 1. Mean direct bilirubin showed a more rapid rise
in the CCK- group as the period of time patients received
TPN increased, whereas the mean levels of direct biliru-
bin were almost flat in the CCK+ group. Although these
results were not statistically different, the use of a linear
regression analysis (the lowest p = .15) revealed a trend.
The percentage of infants with a direct bilirubin >2.0 mg/
dL was 24% and 43% in the CCK+ and CCK- groups, re-
spectively, and was not significant (p = .14). The per-
centage of infants with a direct bilirubin >5.0 mg/dL (se-
. vere cholestasis) was 9.5% and 38% in the CCK+ and CCK-
. groups, respectively, which was significant (p = .015). With
~ longer durations of TPN, total bilirubin levels were also
. noted to be higher in the CCK- group compared with the
. CCK+ group. Indirect bilirubin levels, although somewhat
higher in the CCK- group for the first 3 weeks of the
~ study, showed no difference between groups for other
3 study time points.
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FIG. 1. Serum direct bilirubin levels measured weekly, in both groups of
neonates receiving total parenteral nutrition (TPN) therapy (*p < .05).
After the third week, note the rapid rise and consistently higher levels for
the nontreatment group of patients. Because of a loss of patients in each
group after week 7, only weeks 1 through 7 are shown.
No statistical differences were noted for AST, ALT, LDH,
and alkaline phosphatase levels throughout the study pe-
riod.
No difference was seen in the growth characteristics of
either group as measured by weight gain throughout the
study. At study week 3, body weights were 1.91 ± 1.1 and
2.06 ± 1.1 kg in the CCK+ and CCK- groups, respectively.
Mean serum total protein levels, measured on a weekly
basis, were virtually the same in the two groups. At study
week 3, total protein levels were 4.6 ± 0.9 and 4.6 ± 1.2 g/
dL in the CCK+ and CCK- groups, respectively.
DISCUSSION
Parenteral nutrition-associated cholestasis (PNAC) is
a persistent problem in newborns receiving long-term
parenteral nutrition.2,11 The etiology of PNAC has not been
identified; however, one hypothesis is that a lack of oral
feedings may lead to biliary stasis.&dquo; Biliary stasis has been
observed in patients receiving prolonged courses of TPN
using ultrasonographic assessment of the gallbladder.13
This stasis may develop secondarily to inadequate hor-
monal stimulation, which is needed for gallbladder con-
traction and intrahepatic bile flow. The gastrointestinal
hormone cholecystokinin, which is normally released dur-
ing enteral feeding and which is needed for bile flow, re-
mains at very low levels during periods of fasting. 14 Chole-
cystokinin has the ability to induce gallbladder contraction
as well as to increase intrahepatic bile flow.’ Therefore,
we hypothesized that cholecystokinin would be efficacious
in the prevention of parenteral nutrition-associated
cholestasis.
In our study, we showed that the CCK-treated neonates
maintained a lower level of direct bilirubins throughout
the duration of the study. The nontreated group, on the
other hand, showed a steady rise in direct bilirubin levels,
demonstrating a defmite trend over the duration of theii
TPN course. A statistically significant difference was
achieved in the ability of CCK to reduce the incidence of
severe cholestasis (direct bilirubin > 5.0 mg/dL); however,
significance was not attained when examining all cases of
PNAC (defined as a direct bilirubin >2.0 mg/dL). The dif-
ficulty in achieving a significant difference was due to the
fairly large standard deviations in mean direct bilirubin
levels in the control group. Further, because most neo-
nates had started on enteral feedings after the fourth week
of the study, only 7 patients remained in each group (CCK+
and CCK-) after the fourth week, which made the attain-
ment of significance more difficult. It has been shown that
higher septic rates can contribute to a worsening of PNAC
and could have contributed to the higher bilirubin levels
in the control group. 15 Septic events, however, were iden-
tical in both groups, making this possibility unlikely. Al-
though our current study was not randomized, we care-
fully selected controls that were matched to our study
patients in terms of the greatest potential risk factors for
the development of PNAC (ie, gestational age, diagnosis,
and duration of TPN).
Studies in young rats receiving TPN have demonstrated
that cholecystokinin is beneficial in reducing the degree
of cholestasis.l6 In a more recent study by Curran et ap7
on the use of Sincalide (CCK) in prepubescent rabbits
maintained on TPN, the authors demonstrated that there
was a reduction in periportal inflammation and fibrosis
but no change in the balloon degeneration of the hepato-
cytes. This group also noted a significant increase in basal
bile flow rates and clearance of sulfobromophthalein in
the CCK-treated rabbits. Based on these reports, Rintala
et al7 and our own group8 have successfully treated a num-
ber of premature and postsurgical neonates who devel-
oped significant degrees of PNAC. In each of these stud-
ies, several neonates attained a significant decline in their
direct bilirubin levels after receiving IV cholecystokinin
for 4 to 14 days. In our own study, several infants failed to
respond to CCK; all were shown to have advanced PNAC
with cirrhosis and subsequently were shown to have liver
failure. The purpose of the current study was to evaluate
the use of CCK in a prophylactic fashion to prevent the
development of PNAC and, thus, cirrhosis.
Other tests of liver function failed to show any clear
trends with CCK treatment. However, no study has shown
that PNAC correlates well with any of these other reported
tests.
Several adverse reactions may occur with the adminis-
tration of cholecystokinin; these include gastrointestinal
cramping and feeding intolerance because of spasm of the
pyloric sphincter. No neonate developed any substantiated
side effect during treatment with the CCK-octapeptide.
Most likely this was due to the fairly low doses of the drug
used in this study compared with our previous investiga-
tion in which doses several times higher were used to treat
clinically advanced PNAC
, In conclusion, use of cholecystokinin-octapeptide ap-
pears to be associated with a trend toward lower direct
bilirubin levels in neonates receiving long-term TPN. Based
: on this finding, we believe that cholecystokinin-octapep-
, tide may be effective in preventing the development of, or
~ a reduction in the degree of parenteral nutrition-associ-
, ated cholestasis in neonates. Future, randomized prospec-
, tive studies should confirm the findings presented here.
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